Use of dexamethasone in patients with high-grade glioma: A clinical practice guideline

Current Oncology

Volumn 21, Issue 3, 2014, Pages 493-503

  Kostaras, X ^a   Cusano, F ^b   Kline, G A ^c   Roa, W ^d   Easaw, J ^b  

^a ALBERTA HEALTH SERVICES   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d CROSS CANCER INSTITUTE   (Canada)

Author keywords

Clinical practice guidelines; Corticosteroids; Dexamethasone; High grade glioma

Indexed keywords

DEXAMETHASONE;

ARTICLE; AVASCULAR NECROSIS; BIBLIOGRAPHIC DATABASE; BRAIN EDEMA; BRAIN METASTASIS; BRAIN TUMOR; CANDIDIASIS; CORTICOSTEROID INDUCED MYOPATHY; DEPRESSION; DISEASE SURVEILLANCE; DRUG DOSE REDUCTION; GASTROINTESTINAL HEMORRHAGE; GLIOMA; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOALBUMINEMIA; INSOMNIA; INTESTINE PERFORATION; MANIA; MEDICATION THERAPY MANAGEMENT; META ANALYSIS (TOPIC); MYOPATHY; OSTEOPOROSIS; PEPTIC ULCER; PNEUMONIA; PRACTICE GUIDELINE; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL; SYSTEMATIC REVIEW (TOPIC); VENOUS THROMBOEMBOLISM;

EID: 84902651652     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.21.1769     Document Type: Article

References (42)

1. Drappatz J, Schiff D, Kesari S, Norden AD, Wen PY. Medical management of brain tumor patients. Neurol Clin 2007;25:1035-1071.
2. Weissman DE, Janjan NA, Erickson B, et al. Twice-daily tapering dexamethasone treatment during cranial radiation for newly diagnosed brain metastases. J Neurooncol 1991;11:235-239.
3. Vecht CJ, Hovestadt A, Verbiest HB, van Vliet JJ, van Putten WL. Dose-effect relationship of dexamethasone on Karnofsky performance in metastatic brain tumors: a randomized study of doses of 4, 8, and 16 mg per day. Neurology 1994;44:675-680.
4. Wolfson AH, Snodgrass SM, Schwade JG, et al. The role of steroids in the management of metastatic carcinoma to the brain. A pilot prospective trial. Am J Clin Oncol 1994;17:234-238.
5. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identifcation of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys 1999;43:795-803.
6. Hempen C, Weiss E, Hess CF. Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefts outweigh the side-effects? Support Care Cancer 2002;10:322-328.
7. Millar BM, Bezjak A, Tsao M, Sturdza A, Laperriere N. Defining the impact and contribution of steroids in patients receiving whole-brain irradiation for cerebral metastases. Clin Oncol (R Coll Radiol) 2004;16:339-344.
8. Sturdza A, Millar BA, Bana N, et al. The use and toxicity of steroids in the management of patients with brain metastases. Support Care Cancer 2008;16:1041-1048.
9. Ryken TC, McDermott M, Robinson PD, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neu-rooncol 2010;96:103-114.
10. Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E On behalf of the Obesity Canada Clinical Practice Guidelines Expert Panel. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [summary]. CMAJ 2007;176:S1-S13.
11. Gaspar LE, Videtic GMM, Gore EM, et al. On behalf of the Expert Panel on Radiation Oncology-Brain Metastases. American College of Radiology: ACR Appropriateness Criteria. Pre-irradiation Evaluation and Management of Brain Metastases. Reston, VA: American College of Radiology; 2011. [Available online at: http://www.acr.org/~/media/ACR/Documents/AppCriteria/Oncology/PreIrradiationEvaluationBrainMetastases.pdf; cited February 27, 2013]
12. Soffetti R, Ruda R, Mutani R. Management of brain metas-tases. J Neurol 2002; 249:1357-1369.
13. Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefts and pitfalls. Expert Rev Clin Pharmacol 2011; 4: 233-242.
14. Roth P, Wick W, Weller M. Steroids in neurooncol-ogy: actions, indications, side-effects. Curr Opin Neurol 2010;23:597-602.
15. BC Cancer Agency (bcca). Home > Health Professionals Info > Cancer Management Guidelines > Neuro-Oncology > 5. Management [Web resource]. Vancouver, BC: bcca; 2004. [Available at: http://www.bccancer.bc.ca/HPI/CancerManagementGuidelines/NeuroOncology/Management Policies/default.htm; cited February 27, 2013]
16. Cancer Council Australia. Home > Health professionals > Clinical guidelines > Brain tumours > Clinical Practice Guidelines for the Management of Adult Gliomas: Astrocytomas and Oligodendrogliomas [Web resource]. 2009. [Available at: http://www.cancer.org.au/Healthprofessionals/clinicalguidelines/braintumours.htm; cited February 27, 2013]
17. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Tumours. Ver. 2.2013. Fort Washington, PA: nccn; 2013. [Current version available online at: http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf (free registration required); cited April 3, 2013]
18. Nahaczewski AE, Fowler SB, Hariharan S. Dexamethasone therapy in patients with brain tumors-a focus on tapering. J Neurosci Nurs 2004;36:340-343.
19. Szabo GC, Winkler SR. Withdrawal of glucocorticoid therapy in neurosurgical patients. Surg Neurol 1995;44:498.
20. Batchelor TT, Byrne TN. Supportive care of brain tumor patients. Hematol Oncol Clin North Am 2006;20:1337-1361.
21. Weissman DE, Dufer D, Vogel V, Abeloff MD. Corticosteroid toxicity in neuro-oncology patients. J Neurooncol 1987; 5:125-128.
22. Hoogwerf B, Danese RD. Drug selection and the management of corticosteroid-related diabetes mellitus. Rheum Dis Clin North Am 1999;25:489-505.
23. Clore JN, Thurby-Hay L. Glucocorticoid-induced hypergly-cemia. Endocr Pract 2009;15:469-474.
24. Wen PY, Schiff D, Kesari S, Drappatz J, Gigas DC, Doherty L. Medical management of patients with brain tumors. J Neurooncol 2006;80:313-332.
25. Pereira RM, Freire de Carvalho J. Glucocorticoid-induced myopathy. Joint Bone Spine 2011;78:41-44.
26. Fardet L, Kassar A, Cabane J, Flahault A. Corticosteroid-induced adverse events in adults: frequency, screening and prevention. Drug Saf 2007;30:861-881.
27. LaPier TK. Glucocorticoid-induced muscle atrophy. The role of exercise in treatment and prevention. J Cardiopulm Rehabil 1997;17:76-84.
28. Frieze DA. Musculoskeletal pain associated with corti-costeroid therapy in cancer. Curr Pain Headache Rep 2010;14:256-260.
29. Papaioannou A, Morin S, Cheung AM, et al. On behalf of the Scientifc Advisory Council of Osteoporosis Canada. 2010 Clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ 2010;182:1864-1873.
30. Gerd and peptic ulcer disease: evidence and chart. In: Jensen B, Regier LD, eds. RxFiles: Drug Comparison Charts. 8th ed. Saskatoon, SK: Saskatoon Health Region; 2010: 41.
31. Poetker DM, Reh DD. A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngol Clin North Am 2010;43:753-768.
32. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Distress Management. Ver. 2.2013. Fort Washington, PA: nccn; 2013. [Current version available online at: http://www.nccn.org/professionals/physician_gls/pdf/distress.pdf (free registration required); cited February 27, 2013]
33. BC Cancer Agency (bcca). Home > Patient/Public Info > Coping with Cancer > Managing Symptoms and Side Effects > Fatigue > Professional Management: Managing Your Cancer Treatment-Related Fatigue [Web resource]. Vancouver, BC: bcca; 2006. [Available online at: http://www.bccancer.bc.ca/PPI/copingwithcancer/symptoms/fatigue/pmgt.htm; cited February 27, 2013]
34. Sleep disorders: sedatives. In: Jensen B, Regier LD, eds. RxFiles: Drug Comparison Charts. 8th ed. Saskatoon, SK: Saskatoon Health Region; 2010: 111.
35. Gilbert DN, Moellering RC, Eliopoulos GM, Chambers HF, Saag MS, eds. The Sanford Guide to Antimicrobial Therapy. 41st ed. Sperryville, VA: Antimicrobial Therapy; 2011.
36. Lyman GH, Khorana AA, Falanga A, et al. On behalf of the American Society of Clinical Oncology. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-5505.
37. National Comprehensive Cancer Network (nccn). NCCN Clinical Practice Guidelines in Oncology: Venous Throm-boembolic Disease. Ver. 1.2013. Fort Washington, PA: nccn; 2013. [Current version available online at: http://www.nccn.org/professionals/physician_gls/pdf/vte.pdf (free registration required); cited February 27, 2013]
38. Wen PY, Lee EQ. Anticoagulant and antiplatelet therapy in patients with brain tumors [Web resource]. Boston, MA: Up-ToDate; n.d. [Current version available online at: http://www. uptodate.com/contents/anticoagulant-and-antiplatelet-therapy-in-patients-with-brain-tumors (membership required); cited January 2, 2012]
39. Derr RL, Ye X, Islas MU, Desideri S, Saudek CD, Grossman SA. Association between hyperglycemia and survival in patients with newly diagnosed glioblastoma. J Clin Oncol 2009;27:1082-1086.
40. McGirt MJ, Chaichana KL, Gathinji M, et al. Persistent outpatient hyperglycemia is independently associated with decreased survival after primary resection of malignant brain astrocytomas. Neurosurgery 2008;63:286-291.
41. Messer J, Reitman D, Sacks HS, Smith H Jr, Chalmers TC. Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983;309:21-24.
42. Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994;236:619-632.